292 related articles for article (PubMed ID: 22127535)
1. Molecular targeted agents for gastric and gastroesophageal junction cancer.
Oshima T; Masuda M
Surg Today; 2012 Apr; 42(4):313-27. PubMed ID: 22127535
[TBL] [Abstract][Full Text] [Related]
2. Advanced gastric cancer (GC) and cancer of the gastro-oesophageal junction (GEJ): focus on targeted therapies.
Cappetta A; Lonardi S; Pastorelli D; Bergamo F; Lombardi G; Zagonel V
Crit Rev Oncol Hematol; 2012 Jan; 81(1):38-48. PubMed ID: 21256046
[TBL] [Abstract][Full Text] [Related]
3. Angiogenesis inhibitors in gastric and gastroesophageal junction cancer.
Roviello G; Petrioli R; Marano L; Polom K; Marrelli D; Perrella A; Roviello F
Gastric Cancer; 2016 Jan; 19(1):31-41. PubMed ID: 26329368
[TBL] [Abstract][Full Text] [Related]
4. Targeted Therapies for Advanced Oesophagogastric Cancer: Recent Progress and Future Directions.
Young K; Chau I
Drugs; 2016 Jan; 76(1):13-26. PubMed ID: 26620367
[TBL] [Abstract][Full Text] [Related]
5. Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review.
Chen LT; Oh DY; Ryu MH; Yeh KH; Yeo W; Carlesi R; Cheng R; Kim J; Orlando M; Kang YK
Cancer Res Treat; 2017 Oct; 49(4):851-868. PubMed ID: 28052652
[TBL] [Abstract][Full Text] [Related]
6. Targeted therapies in gastroesophageal cancer.
Kasper S; Schuler M
Eur J Cancer; 2014 May; 50(7):1247-58. PubMed ID: 24495747
[TBL] [Abstract][Full Text] [Related]
7. Genomic alterations in advanced esophageal cancer may lead to subtype-specific therapies.
Forde PM; Kelly RJ
Oncologist; 2013; 18(7):823-32. PubMed ID: 23853247
[TBL] [Abstract][Full Text] [Related]
8. Gastric Carcinoma at the Era of Targeted Therapies.
Dreanic J; Dhooge M; Sion E; Brezault C; Chaussade S; Coriat R
Curr Drug Targets; 2016; 17(15):1818-1826. PubMed ID: 25944013
[TBL] [Abstract][Full Text] [Related]
9. New advances in targeted gastric cancer treatment.
Lazăr DC; Tăban S; Cornianu M; Faur A; Goldiş A
World J Gastroenterol; 2016 Aug; 22(30):6776-99. PubMed ID: 27570417
[TBL] [Abstract][Full Text] [Related]
10. Targeted therapies with chemoradiation in esophageal cancer: development and future directions.
Hong TS; Wo JY; Kwak EL
Semin Radiat Oncol; 2013 Jan; 23(1):31-7. PubMed ID: 23207045
[TBL] [Abstract][Full Text] [Related]
11. A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction.
Shah MA; Cho JY; Tan IB; Tebbutt NC; Yen CJ; Kang A; Shames DS; Bu L; Kang YK
Oncologist; 2016 Sep; 21(9):1085-90. PubMed ID: 27401892
[TBL] [Abstract][Full Text] [Related]
12. Targeting the MET Pathway in Gastric and Oesophageal Cancers: Refining the Optimal Approach.
Lee J; Tran P; Klempner SJ
Clin Oncol (R Coll Radiol); 2016 Aug; 28(8):e35-44. PubMed ID: 26880063
[TBL] [Abstract][Full Text] [Related]
13. Update on Gastroesophageal Adenocarcinoma Targeted Therapies.
Maron SB; Catenacci DVT
Hematol Oncol Clin North Am; 2017 Jun; 31(3):511-527. PubMed ID: 28501091
[TBL] [Abstract][Full Text] [Related]
14. Target Therapy for Esophageal Adenocarcinoma.
Lam KO; Kwong DLW
Methods Mol Biol; 2018; 1756():51-65. PubMed ID: 29600359
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapies for advanced and metastatic adenocarcinoma of the gastroesophageal junction: is there something new?
Pasini F; Fraccon AP; Modena Y; Bencivenga M; Giacopuzzi S; La Russa F; Gusella M; de Manzoni G
Gastric Cancer; 2017 Jan; 20(1):31-42. PubMed ID: 27568322
[TBL] [Abstract][Full Text] [Related]
16. Novel Targeted Therapies for Esophagogastric Cancer.
Maron SB; Catenacci DV
Surg Oncol Clin N Am; 2017 Apr; 26(2):293-312. PubMed ID: 28279470
[TBL] [Abstract][Full Text] [Related]
17. Optimal management of gastroesophageal junction cancer.
Greally M; Agarwal R; Ilson DH
Cancer; 2019 Jun; 125(12):1990-2001. PubMed ID: 30973648
[TBL] [Abstract][Full Text] [Related]
18. Esophagogastric cancer: targeted agents.
Ku GY; Ilson DH
Cancer Treat Rev; 2010 May; 36(3):235-48. PubMed ID: 20122806
[TBL] [Abstract][Full Text] [Related]
19. Targeting the human EGFR family in esophagogastric cancer.
Okines A; Cunningham D; Chau I
Nat Rev Clin Oncol; 2011 Apr; 8(8):492-503. PubMed ID: 21468131
[TBL] [Abstract][Full Text] [Related]
20. Biomarker-driven targeted therapies for gastric/gastro-esophageal junction malignancies.
Kim S; Barzi A; Rajdev L
Semin Oncol; 2018 Jun; 45(3):133-150. PubMed ID: 30262395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
